Cargando…
Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
BACKGROUND: Budesonide foam is effective in inducing clinical remission in ulcerative colitis (UC) patients with active proctosigmoiditis. The aim of this study was to evaluate the duration of remission and predictors of relapse in UC patients who achieved clinical remission and mucosal healing by 6...
Autores principales: | Naganuma, Makoto, Hirai, Fumihito, Kobayashi, Kiyonori, Watanabe, Kenji, Takeuchi, Ken, Aoyama, Nobuo, Nozawa, Hiroshi, Motoya, Satoshi, Ohmori, Toshihide, Harada, Akio, Nagai, Yushi, Abe, Takayuki, Yamada, Yoji, Inagaki, Katsutoshi, Shimizu, Naoki, Kanai, Takanori, Watanabe, Mamoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681969/ https://www.ncbi.nlm.nih.gov/pubmed/31381615 http://dx.doi.org/10.1371/journal.pone.0220413 |
Ejemplares similares
-
Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
por: Naganuma, Makoto, et al.
Publicado: (2017) -
Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis
por: Naganuma, Makoto, et al.
Publicado: (2016) -
Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
por: Hibi, Toshifumi, et al.
Publicado: (2020) -
Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021) -
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis
por: Rubin, David T., et al.
Publicado: (2015)